Clinical features and in vivo confocal microscopy assessment in 12 patients with ocular cicatricial pemphigoid
Author:
Fund Project:

Supported by the National Natural Science Foundation of China (No.81070755; No.81071301).

  • Article
  • | |
  • Metrics
  • |
  • Reference [30]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To describe the clinical features and microstructural characteristics assessed by in vivo confocal microscopy (IVCM) in patients with ocular cicatricial pemphigoid (OCP). METHODS: A descriptive, uncontrolled case series study. Patients diagnosed with OCP were examined by clinical history, slit-lamp biomicroscopy features and IVCM images. The results of direct immunofluorescence (DIF) biopsies and indirect immunofluorescence (IIF) were also recorded. Local and systemic immunosuppressive therapy were administered and adjusted according to response. RESULTS: A total of 12 consecutive OCP patients (7 male, 5 female; mean age 60.42±10.39y) were recruited. All patients exhibited bilateral progressive conjunctival scarring and recurrent chronic conjunctivitis was the most frequent clinical pattern. The mean duration of symptoms prior to diagnosis of OCP was 2.95±2.85y (range: 5mo to 10y). The Foster classification varied from stage I to IV and 20 eyes (83%) were within or greater than Foster stage Ⅲ on presentation. Two of the 12 patients (17%) demonstrated positive DIF; 3 of the 12 (25%) patients reported positive IIF. The mean duration of the follow-up period was 20.17±11.88mo (range: 6 to 48mo). IVCM showed variable degrees of abnormality in the conjuctiva-cornea and conjuctival scarring was detected in all the involved eyes. Corneal stromal cell activation and dendritic cell infiltration presented as ocular surface inflammation, ocular surface keratinization along with the destroyed Vogt palisades was noted in eyes with potential limbal stem cell deficiency. After treatment, remission of ocular surface inflammation was achieved in all the patients, 18 eyes (75%) remained stable, 6 eyes (25%) had recurrent conjunctivitis and cicatrization in 2 eyes (8%) was progressing.  CONCLUSION: As an autoimmune disease, OCP manifests as variable degrees of clinical and laboratory abnormalities with both local and systemic immunosuppressive treatment playing important roles in disease therapy. IVCM can be as a valuable non-invasive technique to assess ocular surface changes in a cellular level with a potential value for providing diagnostic evidence and monitoring therapeutic effects during follow-up.

    Reference
    1 Chan LS. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin Dermatol 2012;30(1):34-37.
    2 Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current anagement. Semin Ophthalmol 2011;26(4-5):270-277.
    3 Foster CS. Cicatricial pemphigoid. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea: Fundamentals, Diagnosis, and Management. Philadelphia, PA: Mosby Elsevier Inc; 2011:591-599.
    4 Williams GP, Radford C, Nightingale P, Dart JK, Rauz S. Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. Eye (Lond) 2011;25(9):1207-1218.
    5 Dacosta J. Ocular cicatricial pemphigoid masquerading as chronic conjunctivitis: a case report. Clin Ophthalmol 2012;6:2093-2095.
    6 Yan XM, Chen Y, Li HL, Rong B, Yang SL. Retrospective analysis of ocular cicatricial pemphigoid. Zhonghua Yan Ke Za Zhi 2010;46(9):781-784.
    7 Tauber J. Ocular cicatricial pemphigoid. Ophthalmology 2008;115(9):1639-1640.
    8 Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res 2004;23(6):579-592.
    9 Sobolewska B, Deuter C, Zierhut M. Current medical treatment of ocular mucous membrane pemphigoid. Ocul Surf 2013;11(4):259-266.
    10 Hingorani M, Lightman S. Ocular cicatricial pemphigoid. Curr Opin Allergy Clin Immunol 2006;6(5):373-378.
    11 Shukla AN, Cruzat A, Hamrah P. Confocal microscopy of corneal dystrophies. Seminars in ophthalmology 2012;27(5-6):107-116.
    12 Nwaneshiudu A, Kuschal C, Sakamoto FH, Anderson RR, Schwarzenberger K, Young RC. Introduction to confocal microscopy. J Invest Dermatol 2012;132(12): e3.
    13 Barabino S, Rolando M. In vivo confocal microscopy of ocular cicatricial pemphigoid. Ophthalmic Surg Lasers Imaging 2006;37(2):175-176.
    14 Foster CS, Sainz De La Maza M. Ocular cicatricial pemphigoid review. Curr Opin Allergy Clin Immunol 2004;4(5):435-439.
    15 Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermat 2002;138(3):370-379.
    16 Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 2004;111(1):45-52.
    17 Jonkman MF, Groot AC, Slegers TP, Jone MC, Pas HH. Immune diagnosis of pure ocular mucous membrane pemphigoid: indirect immuno fluorescence versus immunoblot. Eur J Dermatol 2009;19(5):456-460.
    18 Friedman J, Marcovich AL, Kleinmann G, Schattner A. Low-dose pulsed intravenous cyclophosphamide for severe ocular cicatricial pemphigoid in elderly patients. Cornea 2014;33(10):1066-1070.
    19 Hatton MP, Raizman M, Foster CS. Exacerbation of undiagnosed ocular cicatricial pemphigoid after repair of involutional entropion. Ophthal Plast Reconstr Surg 2008;24(2):165-166.
    20 Lugovic L, Buljan M, Situm M, Poduje S, Bulat V, Vucic M, Budimir J. Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report. Acta Dermatovenerol Croat 2007;15(4):236-242.
    21 Chang JH, McCluskey PJ. Ocular cicatricial pemphigoid: manifestations and management. Curr Allergy Asthma Rep 2005;5(4):333-338.
    22 Saw VP, Dart JK, Rauz S, Ramsay A, Bunce C, Xing W, Maddison PG, Phillips M. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008;115(2): 253-261. e1.
    23 El Darouti MA, Fakhry Khattab MA, Hegazy RA, Hafez DA, Gawdat HI. Pentoxifylline (anti-tumor necrosis factor drug): effective adjuvant therapy in the control of ocular cicatricial pemphigoid. Eur J Ophthalmol 2011;21(5):529-537.
    24 Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010;117(5):861-869.
    25 Villani E, Baudouin C, Efron N, Hamrah P, Kojima T, Patel SV, Pflugfelder SC, Zhivov A, Dogru M. In vivo confocal microscopy of the ocular surface: from bench to bedside. Curr Eye Res 2014;39(3):213-231.
    26 Goldberg MF. In vivo confocal microscopy and diagnosis of limbal stem cell deficiency. Photographing the palisades of vogt and limbal stem cells. Am J Ophthalmol 2013;156(1):205-206.
    27 Chen W, Dong N, Huang C, Zhang Z1, Hu J1, Xie H1, Pan J1, Liu Z1. Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit. PloS One 2014;9(3): e89205.
    28 Chinnery HR, Pearlman E, McMenamin PG. Cutting edge: Membrane nanotubes in vivo: a feature of MHC class II+ cells in the mouse cornea. J Immunol 2008;180(9): 5779-5783.
    29 Razzaque MS, Foster CS, Ahmed AR. Tissue and molecular events in human conjunctival scarring in ocular cicatricial pemphigoid. Histol Histopathol 2001;16(4):1203-1212.
    30 Neff AG, Turner M, Mutasim DF. Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag 2008;4(3):617-626.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Qin Long, Ya-Gang Zuo, Xue Yang,/et al.Clinical features and in vivo confocal microscopy assessment in 12 patients with ocular cicatricial pemphigoid. Int J Ophthalmol, 2016,9(5):730-737

Copy
Share
Article Metrics
  • Abstract:1562
  • PDF: 644
  • HTML: 307
  • Cited by: 0
Publication History
  • Received:April 09,2014
  • Revised:October 12,2015
  • Online: May 23,2016